Former Director of New Drug Discovery Center at Daewoong Pharmaceutical
Former CSO at I&N Therapeutics

Jeil Pharmaceutical has recruited a new expert in the field of new drug development and is working to strengthen its research and development capabilities.


On June 1, Jeil Pharmaceutical announced that it has appointed Junseok Park, former Director of New Drug Discovery Center at Daewoong Pharmaceutical, as Executive Director (Deputy Director) of its Central Research Institute.

Junseok Park, Deputy Director of Central Research Institute at Jeil Pharmaceutical. Jeil Pharmaceutical

Junseok Park, Deputy Director of Central Research Institute at Jeil Pharmaceutical. Jeil Pharmaceutical

View original image

As Executive Director, Junseok Park will oversee overall research and development at Jeil Pharmaceutical's Central Research Institute. He will take the lead in strengthening global competitiveness through innovative new drug development and accelerating the successful commercialization of next-generation R&D pipelines.


Junseok Park graduated from the Department of Chemistry at Chonnam National University and earned a Ph.D. in Medicinal Chemistry from the College of Pharmacy at Seoul National University. He has served as the Director of New Drug Discovery Center at Daewoong Pharmaceutical and Chief Scientific Officer (Vice President) at I&N Therapeutics. Over the past 30 years, he has been recognized as a results-driven R&D leader, successfully leading the entire process from the discovery of new drug candidates to regulatory approval.


In particular, he spearheaded the development of two domestic blockbuster drugs: Fexuclu (the 34th new drug) for the treatment of gastroesophageal reflux disease and Enblo (the 36th new drug), an SGLT2 inhibitor for diabetes treatment. He has also been directly and indirectly involved in numerous global technology transfers, including those related to autoimmune new drugs.



A Jeil Pharmaceutical representative stated, "We expect that bringing in this expert will drive R&D innovation for Jeil Pharmaceutical's global new drug development," adding, "This will be a key driver in maximizing the value of our R&D pipeline and accelerating our entry into the global market."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing